Rani Therapeutics announced several developments on August 12, 2025, including a research agreement with Chugai, Q2 results filing with the SEC, and presentation of preclinical data.
3 reports, 2 independent
Updated Aug 12
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Rani Therapeutics announced several developments on August 12, 2025, including a research agreement with Chugai, Q2 results filing with the SEC, and presentation of preclinical data.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Rani Therapeutics (United States)
company in San Jose, United States
Nothing else this week.
-
Chugai Pharmaceutical Co.
Switzerland company in Japan
Nothing else this week.
Coverage
Newest first; wire copies grouped- Zacks Small Cap ResearchRANI: Second Quarter Financial Results By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On August 7th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported second quarter 2
- GlobeNewswireRani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclin
- GlobeNewswireRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to S